4-氟-3-甲氧基苯乙酸 | 78495-65-5

• 物质功能分类: 化学试剂 - 有机试剂 - 芳烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-3-甲氧基苯乙酸
• 中文别名: 2-氟-3,4-二甲氧基苯乙酸
• 英文名称: (2-fluoro-3,4-dimethoxyphenyl)acetic acid
• 英文别名: 2-fluorohomoveratric acid；2-(2-Fluoro-3,4-dimethoxyphenyl)acetic acid
• CAS: 78495-65-5
• 化学式: C₁₀H₁₁FO₄
• 分子量: 214.193
• InChiKey: RAXDCPIEIZUGRH-UHFFFAOYSA-N

物化性质

• 熔点：
  103-107℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-氟-3-甲氧基苯乙酸 在 sodium hydroxide 、 氯化亚砜 、 硼烷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-<2-hydroxy-2-(4-methoxyphenyl)>-2-(3,4-dimethoxy-2-fluorophenyl)ethylamine
  参考文献：
  名称：

  Dopamine agonists related to 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol, 6-position modifications

  摘要：

  The N-allyl derivative (SK&F 85174) of 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol (SK&F 82526) retains the DA-1 agonist potency of the latter compound but unlike the parent also shows substantial DA-2 agonist activity. In a previous study of N-substituted benzazepines these combined agonist effects were shown to be uniquely associated with the N-allyl group. A continuation of this research has examined dependency of combined DA-2/DA-1 agonist activities on 6-position modification with the specific objective of developing an agonist with maximum effectiveness and potency at the DA-2 receptor subtype. DA-2 agonist activity was measured in a rabbit ear artery assay, and DA-1 agonist activity was determined in an adenylate cyclase assay. Replacing chloro with bromo retains the activity pattern and the potency of the chloro compound; replacement with a hydrogen causes a decrease of both DA-1 and DA-2 receptor activating potency. Introduction of a 6-methyl group causes loss of DA-2 agonist activity and reduction in DA-1 agonist potency. Substitution with a 6-fluoro provides the best balance of DA-2 and DA-1 agonist activities; this compound was moderately potent in both assays.

  DOI：

  10.1021/jm00384a006
• 作为产物：
  描述：

  2-(2-氟-3,4-二甲氧基苯基)乙腈 在 sodium hydroxide 作用下， 反应 16.0h， 以27 g的产率得到4-氟-3-甲氧基苯乙酸
  参考文献：
  名称：

  Dopamine agonists related to 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol, 6-position modifications

  摘要：

  The N-allyl derivative (SK&F 85174) of 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol (SK&F 82526) retains the DA-1 agonist potency of the latter compound but unlike the parent also shows substantial DA-2 agonist activity. In a previous study of N-substituted benzazepines these combined agonist effects were shown to be uniquely associated with the N-allyl group. A continuation of this research has examined dependency of combined DA-2/DA-1 agonist activities on 6-position modification with the specific objective of developing an agonist with maximum effectiveness and potency at the DA-2 receptor subtype. DA-2 agonist activity was measured in a rabbit ear artery assay, and DA-1 agonist activity was determined in an adenylate cyclase assay. Replacing chloro with bromo retains the activity pattern and the potency of the chloro compound; replacement with a hydrogen causes a decrease of both DA-1 and DA-2 receptor activating potency. Introduction of a 6-methyl group causes loss of DA-2 agonist activity and reduction in DA-1 agonist potency. Substitution with a 6-fluoro provides the best balance of DA-2 and DA-1 agonist activities; this compound was moderately potent in both assays.

  DOI：

  10.1021/jm00384a006

文献信息

• Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins
  作者：Joseph Weinstock、Dimitri Gaitanopoulos、Hye Ja Oh、Francis R. Pfeiffer、Carole B. Karash、Joseph W. Venslavsky、Henry M. Sarau、Kathryn E. Flaim、J. Paul Hieble、Carl Kaiser

  DOI：10.1021/jm00159a010

  日期：1986.9

  fluoro substituent into the 6-position increases dopaminergic potency. Also, in this series replacement of the 7-hydroxyl group with a halogen results in inversion of activity from dopamine receptor agonist to antagonist. The present study was aimed at exploring the possibility that the structure-activity observations in the 3-benzazepine series of dopaminergic agents might be extrapolated to another class

  在一系列7,8-二羟基-1-苯基四氢-3-苯并ze庚因多巴胺受体激动剂中，将氯或氟取代基引入6-位可提高多巴胺能。同样，在该系列中，用卤素取代7-羟基导致活性从多巴胺受体激动剂转化为拮抗剂。本研究旨在探讨将3-benzazepine系列多巴胺能药物的结构活性观察结果推断到另一类多巴胺受体激动剂2-氨基四氢萘的可能性。因此，制备了一系列的氯和氟取代的单和二羟基的2-氨基四氢萘并在D-1和D-2受体相关的测试中评估了多巴胺能性质。将氯取代基引入该系列原型的8位，即 2-氨基-6,7-二羟基四氢化萘（ADTN）产生了对多巴胺受体D-1亚群具有高度选择性的化合物；在与D-1受体相关的测试中，它的作用与ADTN相同或更高，在涉及D-2受体的测试中，有效性大大降低。用8-氟-ADTN观察到了类似的效果。然而，8-氯取代的ADTN的N-（4-羟基苯乙基）-N-丙基衍生物4g显示出显着的D-2结合亲和力。
• 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines
  申请人：SmithKline Corporation

  公开号：US04265890A1

  公开（公告）日：1981-05-05

  Mercapto substituted-2,3,4,5-tetrahydro-1H-3-benzazepines having dopamine receptor blocking activity are prepared from o-quinones or via standard preparative procedures.

  巯基取代的-2,3,4,5-四氢-1H-3-苯并哌啶具有多巴胺受体阻断活性，可通过邻醌或标准制备程序制备。
• 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0080012A1

  公开（公告）日：1983-06-01

  6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate to prepare mercapto substituted-2,3,4,5-tetrahydro-1H-3- benzazepines as disclosed in European Patent Application No. 79102279.1.

  欧洲专利申请 79102279.1 号中公开的 6-氯-3-甲基-2,3,4,5-四氢-1H-3-苯并氮杂卓、其酸加成盐及其作为中间体制备巯基取代的-2,3,4,5-四氢-1H-3-苯并氮杂卓的用途。
• Benz-trisubstituted 2-aminotetralins
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0209275A1

  公开（公告）日：1987-01-21

  The invention relates to compounds of the formula: wherein R1 and R2 are each hydrogen, n-propyl, n-butyl or 4-hydroxyphenetyl; X is hydrogen or halo; and Y is hydrogen or halo provided that one of X and Y is halo and the other is hydrogen. Also disclosed are methods for the preparation of the compounds, pharmaceutical compositions containing them and their activity as dopaminergic receptor antagonists.

  本发明涉及式的化合物： 其中 R1 和 R2 各为氢、正丙基、正丁基或 4-羟基苯乙基； X为氢或卤代；Y为氢或卤代，条件是X和Y中的一个为卤代，另一个为氢。还公开了制备这些化合物的方法、含有这些化合物的药物组合物及其作为多巴胺能受体拮抗剂的活性。
• 2,3,4,5-Tetrahydro-1H-3-Benzazepines, process for their production and pharmaceutical compositions having dopamine receptor blocking activity
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0007070B1

  公开（公告）日：1983-01-19